Citable filing context

RMD filing events and research context

Server-rendered

RMD's research view summarizes recent SEC filing context, starting with mda_quarterly from May 1, 2026.

RMD filing events and research context
FiledItemContext
May 1, 2026mda_quarterlyResMed reported strong financial performance for the quarter ended March 31, 2026, with net revenue reaching $1.4 billion, an 11% increase year-over-year. Growth was driven by robust demand for its Sleep and Breathing Health segment, specifically in device and mask sales across both U.S. and international markets. The company’s gross margin expanded significantly to 62.2%, up from 59.3% in the prior-year period, attributed to manufacturing and logistics efficiencies and lower component costs. The company continues to prioritize innovation, investing $94.3 million in research and development, with a focus on its AirSense 11 platform and digital cloud-based health software. The Residential Care Software segment also contributed to growth, led by the MEDIFOX DAN, Home and Hospice, and Home Medical Equipment verticals. Financially, ResMed remains well-positioned with $1.7 billion in cash and cash equivalents and $1.5 billion available under its revolving credit facility. Capital allocation remains disciplined, highlighted by $500 million in share repurchases during the first nine months of the fiscal year. While the company faces risks related to global minimum tax regulations under Pillar Two and potential supply chain volatility, management maintains a positive outlook, supported by a strong product pipeline and a strategic shift toward home-based care.
Jan 30, 2026mda_quarterlyResMed reported strong financial performance for the three months ended December 31, 2025, with net revenue reaching $1.4 billion, an 11% increase year-over-year. Growth was driven by robust demand for its Sleep and Breathing Health segment, which saw a 12% revenue increase, and its Residential Care Software business, which grew 7%. The company’s gross margin expanded significantly to 61.8% from 58.6% in the prior-year period, attributed to manufacturing and logistics efficiencies and improved component costs. Key product highlights include the AirSense 11 device, which features advanced digital and connectivity capabilities. Operating expenses rose due to increased employee-related costs, marketing investments, and expenses related to the VirtuOx acquisition. The company also recorded $5.9 million in restructuring charges during the quarter related to workforce planning. ResMed maintains a solid liquidity position with $1.4 billion in cash and cash equivalents and $1.5 billion available under its revolving credit facility. Capital allocation remains focused on R&D, which received $91 million in funding, and shareholder returns, including $325 million in share repurchases during the six-month period. Management expects current liquidity to be sufficient for operations and capital requirements beyond the next 12 months, despite potential tax impacts from global Pillar Two minimum tax regulations.
Oct 31, 2025mda_quarterlyResMed reported strong financial performance for the quarter ended September 30, 2025, with net revenue reaching $1.34 billion, a 9% increase year-over-year. Growth was driven by robust demand for devices and masks within the Sleep and Breathing Health segment, which grew 10% to $1.17 billion. The Residential Care Software segment also contributed, rising 6% to $166.1 million, bolstered by the MEDIFOX DAN business despite softness in the Senior Living and Long-Term Care verticals. Profitability improved significantly, with gross margin expanding to 61.5% from 58.6% in the prior-year period, attributed to manufacturing efficiencies and lower component costs. Diluted earnings per share rose 12% to $2.37. The company continues to prioritize innovation, investing $87.3 million in research and development, particularly for the AirSense 11 platform. Operationally, ResMed recorded $15.8 million in restructuring charges related to workforce planning. The effective tax rate increased to 22.0%, reflecting the impact of global Pillar Two minimum tax requirements. Liquidity remains solid, with $1.38 billion in cash and equivalents and $1.5 billion available under its revolving credit facility. Capital allocation remains focused on strategic investments, dividends, and a share repurchase program, under which $150 million was deployed during the quarter.

Source: SEC EDGAR filing text and events; period May 1, 2026; filed May 1, 2026.

Continue research

Keep researching RMD

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →